Contrast Enhanced Mammography

DEVICE7 trials

Sponsors

Dana-Farber Cancer Institute, Karolinska Institutet, University of Arizona, Margarita Louise Zuley, M.D. Anderson Cancer Center

Conditions

Atypical Ductal HyperplasiaBreast CancerBreast Carcinoma in SituCalcificationDCIS

Phase 2

Contrast-Enhanced Spectral Mammography (CESM)

RecruitingNCT06311695

European Institute of OncologyBreast Cancer

Start: 2020-11-16End: 2025-12-31Target: 263Updated: 2024-06-24

Phase 4

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

RecruitingNCT05206331

Margarita Louise ZuleyBreast Cancer

Start: 2022-02-01End: 2027-11-30Target: 2100Updated: 2025-10-08

Unknown Phase

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

TerminatedNCT03505372

Dana-Farber Cancer InstituteAtypical Ductal Hyperplasia

Start: 2018-05-10End: 2019-06-28Updated: 2020-02-11

KARMA Kontrast Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer

Karolinska InstitutetBreast Cancer

Start: 2021-10-01End: 2024-05-31Target: 420Updated: 2023-11-18

Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients

WithdrawnNCT04770714

University of ArizonaBreast Cancer

Start: 2021-01-19End: 2025-01-31Updated: 2024-02-29

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

RecruitingNCT05667532

M.D. Anderson Cancer CenterBreast Cancer

Start: 2022-12-05End: 2028-12-31Target: 1000Updated: 2026-01-09

The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS

Not yet recruitingNCT06217458

Clinical Hospital Center RijekaBreast Carcinoma in Situ, Calcification, DCIS

Start: 2025-03-01End: 2027-01-01Target: 100Updated: 2025-01-06